Novel Sphingomyelin Biomarkers for Brain Glioma and Associated Regulation Research on the PI3K/Akt Signaling Pathway

Xiao-Hui Zhai
Sun Yat-Sen University, zhaixh@zju.edu.cn

Jian Xiao
Sun Yat-Sen University

Jie-Kai Yu
Zhejiang University School of Medicine

Hong Sun
University of Nevada, Las Vegas, hong.sun@unlv.edu

Shu Zheng
Zhejiang University School of Medicine, zhengshu@zju.edu.cn

Follow this and additional works at: https://digitalscholarship.unlv.edu/chem_fac_articles

Part of the Oncology Commons

Repository Citation
Zhai, X., Xiao, J., Yu, J., Sun, H., Zheng, S. (2019). Novel Sphingomyelin Biomarkers for Brain Glioma and Associated Regulation Research on the PI3K/Akt Signaling Pathway. Oncology Letters, 18(6), 6207-6213. Spandidos Publications.
http://dx.doi.org/10.3892/ol.2019.10946

This Article is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV with permission from the rights-holder(s). You are free to use this Article in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/or on the work itself.

This Article has been accepted for inclusion in Chemistry and Biochemistry Faculty Publications by an authorized administrator of Digital Scholarship@UNLV. For more information, please contact digitalscholarship@unlv.edu.
Novel sphingomyelin biomarkers for brain glioma and associated regulation research on the PI3K/Akt signaling pathway

XIAO-HUI ZHAI1,2*, JIAN XIAO1*, JIE-KAI YU2, HONG SUN3 and SHU ZHENG2

1Department of Medical Oncology, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510655; 2Cancer Institute, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China; 3Department of Chemistry and Biochemistry, University of Nevada, Las Vegas, NV 89135, USA

Received September 3, 2018; Accepted July 9, 2019

DOI: 10.3892/ol.2019.10946

Abstract. Glioma is one of the most common malignant tumor types of the central nervous system. It is necessary to identify biomarkers and novel therapeutic targets for glioma. The purpose of the present study was to distinguish lipid biomarkers with differential expression patterns in glioma tissues and normal brain tissues by matrix assisted laser desorption/ionization (MALDI)-imaging and MALDI-time of flight (TOF)-mass spectrometry (MS). Additionally, identification of lipid biomarkers was performed to describe novel therapeutic targets for glioma treatment. A total of six tissues from three patients with glioma and three control patients with traumatic brain injury were analyzed using UltrafleXtreme MALDI-TOF/TOF. The expression levels of 15 lipid peaks were higher in the TBT samples compared with in the GBT samples. The expression levels of another 16 lipid peaks were higher in the GBT samples compared with in the TBT samples. 14 peaks were identified as sphingomyelins using MS/MS. Additional results were also obtained from experiments using the glioma cell line U373-MG. These results indicated that treatment with the drug desipramine (Desi) inhibited the accumulation of ceramide on the cell membranes of glioma cells. Treatment with Desi inhibited the activation of insulin-like growth factor-1 receptor and inhibited the activation of proteins in the PI3K/Akt signaling pathway.

Introduction

Glioma is the most common type of malignant brain tumor in adults worldwide (1,2). The principal diagnosis methods for patients with glioma include disease history questionnaires, nervous system physical examination and imaging examination with different modalities (3). Since early glioma prediction and diagnosis is difficult, the majority of patients are diagnosed at a late stage. Typically, treatment for patients with glioma involves maximal safe surgical resection, followed by chemotherapy and radiotherapy. The prognosis of patients with glioma is frequently poor due to its aggressive properties (4,5). Hence, there is an urgent need to identify novel biomarkers for glioma diagnosis and novel therapeutic targets to improve patient survival.

Protein and lipid are two types of diagnostic biomarkers for glioma (6-8). Biomarkers may be identified from patient samples, including serum, cerebrospinal fluid (CSF) and glioma cells (9). Capillary morphogenesis protein 2 (CMG2) has been identified as a prognostic biomarker for glioma, and CMG2 increased expression is associated with increased tumor grade and poor patient survival (10). The effect of protein biomarker T-LAK cell-originating protein kinase (TOPK) expression on the outcome in malignant glioma has been previously reported, revealing that low TOPK expression is an independent predictor of longer overall survival (11). Ribom et al (12) performed a comparative proteomics analysis with CSF samples from glioma cases and revealed that α-2-Heremans-Schmid glycoprotein was highly expressed in the CSF of patients with low-grade disease. Iwadate et al (13) conducted survival prediction research in glioma based on proteomic analysis and identified 37 protein biomarkers.

In addition to protein biomarkers, lipid biomarkers are also required for the diagnosis and treatment of glioma. The matrix assisted laser desorption/ionization (MALDI)-imaging technique has been widely used in lipid biomarker research (14-16). Wildburger et al (15) identified lipids directly from glioblastoma tissues by MALDI-imaging mass spectrometry (MS), and a number of species of signaling lipids were observed. Shrivas et al (17) identified phospholipids in mouse liver and cerebellum tissue sections using an ionic matrix for enhanced MALDI-imaging MS.

Correspondence to: Dr Xiao-Hui Zhai, Department of Medical Oncology, The Sixth Affiliated Hospital of Sun Yat-sen University, 26 Yuancong Erhemg Road, Guangzhou, Guangdong 510655, P.R. China. E-mail: zhaihx@zju.edu.cn

Professor Shu Zheng, Cancer Institute, The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou, Zhejiang 310009, P.R. China. E-mail: zhengshu@zju.edu.cn

*Contributed equally

Key words: glioma, matrix assisted laser desorption/ionization-imaging, lipid biomarkers, sphingomyelin, PI3K/Akt signaling pathway
In the present study, three glioma brain tissue (GBT) samples and three trauma brain tissue (TBT) samples were collected to identify lipid biomarkers using MALDI-time of flight (TOF)-tandem mass spectrometry (MS/MS). The lipid biomarkers with differential expression were selected and identified. The expression of a number of lipid biomarkers with potential clinical significance was verified using the MALDI-imaging technique. In order to reveal the regulatory mechanisms of lipid biomarkers in glioma signaling pathways, the glioma cell line U373-MG was cultured, and additional research was performed regarding the PI3K/AKT signaling pathway.

Materials and methods

Brain tissue samples. In the present study, three GBT samples from patients with glioma (two women aged 46 and 55 years and one man aged 60 years) and three TBT samples from patients with traumatic brain injury (two men aged 48 and 50 years and one man aged 60 years) were collected following neurosurgery at The First Affiliated Hospital of Zhejiang University School of Medicine (Hangzhou, China) in December 2013. Informed consent was obtained from participants for the use of their tissues in the present study. All diagnoses of glioma were histopathologically confirmed.

Glioma cell culture. The human glioma cell line U373-MG was purchased from American Type Culture Collection (ATCC). The U373-MG ATCC cell line is a U-251 derivative (ATCC). The U373-MG cells were cultured in the new medium with antibody at 37˚C with 5% CO₂. The cells were grown at 37˚C with 5% CO₂ with 2% FBS containing 2% FBS without antibody. Subsequently, DMEM with 2% FBS was added into the dishes. The prepared dishes were placed into the CO₂ incubator of a laser scanning confocal fluorescence microscope. IGF-1R signal was recorded using laser scanning confocal microscopy.

Cell immunostaining. U373-MG cells were cultured in small glass dishes as aforementioned. When cells reached 60-75% of the dishes, the medium was discarded and the cells were washed once with 1 ml PBS. A volume of 1 ml fixation and permeabilization solution (BD Biosciences) was added into the dish, which was kept in the dark for 1 h at 4˚C. The fixing reagent was discarded and the dish was washed once with 1 ml PBS. Goat serum (5%; Jackson Immuno Research) in PBS was used for blocking at room temperature for 1 h. The cells were incubated with mouse monoclonal primary antibody against ceramide (Enzo Life Sciences; cat. no. ALX-804-196; 1:10) at 4˚C overnight. Following three washes with PBS, the cells were incubated with goat anti-mouse IgG secondary antibody (AF647-conjugated; Jackson Immunologicals; cat. no. 115-606-146; 1:300) for 1 h in the dark at room temperature. The dish was washed three times with PBS and visualized using laser scanning confocal microscopy.

For the regulation of IGF-1R expression, U373-MG cells were divided into the DMSO and Desi groups. Cells from the DMSO group represented the control group and were treated with DMSO only and stimulated with insulin for 30 min. Cells from the Desi group were treated with the drug Desi and stimulated with insulin for 30 min.

Western blotting. The glioma cell line U373-MG was lysed with NP40 lysis buffer (Thermo Fisher Scientific, Inc.). The protein density in each sample was determined by ultraviolet spectrometry and adjusted to the same density using loading buffer. Total protein (5 µg) was separated by SDS-PAGE (10% gel) and transferred onto PVDF membranes (EMD Millipore). The membranes were blocked at 4˚C overnight with blocking buffer (pH 7.6) containing 5% nonfat dried milk and incubated with rabbit anti-human monoclonal antibody, which was purchased from Cell Signaling Technology, Inc. Immunoreactive proteins were stained using a chemiluminescent detection system. Membranes were subsequently washed with stripping solution for 1 h and treated as aforementioned, with mouse β-actin antibody (ProteinTech Group, Inc.) as an internal control. The relative target protein expression levels were normalized to those of β-actin.

For the regulation of PI3K/Akt pathway, U373-MG cells were divided into the DMSO and Desi groups. Cells from the DMSO group represented the control group and were treated with DMSO only. Cells from the Desi group were treated with the drug Desi. Both groups were then stimulated with insulin for 15, 30 and 60 min. Western blot analysis of these samples was performed to observe the PI3K/Akt pathway.

Statistical analysis. ClinProTools™ software (version 2.2; Bruker Corporation) was used to perform the statistical analysis of the peaks. Wilcoxon rank-sum test was used to compare data from TBT and GBT groups. Data are presented as the means ± standard deviation. Each experiment was repeated.
Results

Screening of lipid biomarkers between GBT and TBT samples.
In the present study, three GBT samples and three TBT samples were collected, sliced and analyzed by MALDI-TOF-MS. The mass spectrum peaks were analyzed using FlexImaging software Ver3.0. Increased attention was paid to the differential expression peaks of lipid biomarkers in GBT and TBT samples. A total of 15 lipid peaks exhibited a higher expression intensity in normal control TBT samples compared with GBT samples (Table I). Another 16 lipid peaks exhibited a higher expression intensity in GBT samples compared with normal control TBT samples (Table II).

The expression intensity of the lipid peaks of 798.57, 722.55, 799.56, 769.58 and 783.79 m/z was markedly increased in the TBT samples compared with the GBT samples (Table I). Taking the peak of 798.57 m/z as an example, the expression intensity of 798.57 m/z in TBT samples was 198.68±67.29 and in GBT samples was 14.34±11.75. Similarly, the expression intensity of 722.55 m/z in TBT samples was 122.60±42.17 and in GBT samples was 9.37±5.57. The expression intensity of 799.56 m/z in TBT samples was 90.11±32.72 and in GBT samples was 7.11±5.92. The expression intensity of 800.56 m/z in TBT samples was 64.7±23.62 and in GBT samples was 5.92±4.26. The expression intensity of 769.58 (SM) m/z in TBT samples was 94.3±34.4 and in GBT samples was 9.06±5.37. The expression intensity of 828.57 m/z in TBT samples was 14.17±4.68 and in GBT samples was 3.32±2.06. The expression intensity of 849.65 m/z in TBT samples was 13.13±4.42 and in GBT samples was 2.93±2.09. The expression intensity of 770.56 m/z in TBT samples was 56.06±20.65 and in GBT samples was 7.46±4.99. The expression intensity of 773.54 m/z in TBT samples was 30.43±18.96 and in GBT samples was 5.18±3.47. The expression intensity of 755.58 (SM) m/z in TBT samples was 14.11±5.83 and in GBT samples was 6.11±3.92. The expression intensity of 753.60 (SM) m/z in TBT samples was 70.94±31.10 and in GBT samples was 10.69±7.62. The expression intensity of 771.57 (SM) m/z in TBT samples was 27.07±10.97 and in GBT samples was 6.23±2.62. The expression intensity of 783.79 (SM) m/z in TBT samples was 99.88±38.85 and in GBT samples was 42.26±21.45. The expression intensity of 797.60 (SM) m/z in TBT samples was 17.00±6.60 and in GBT samples was 10.27±3.59.

GBT, glioma brain tissue; SD, standard deviation; SM, sphingomyelin; TBT, trauma brain tissue.

Table I. Lipid peaks with higher expression in TBT samples compared with GBT samples.

| Bio-marker (m/z) | P-value | Expression in TBT (mean ± SD) | Expression in GBT (mean ± SD) |
|------------------|---------|-------------------------------|-------------------------------|
| 798.57           | <1x10^-6| 198.68±67.29                 | 14.34±11.75                  |
| 722.55           | <1x10^-6| 122.60±42.17                 | 9.37±5.57                    |
| 848.64           | <1x10^-6| 26.64±9.18                   | 3.44±2                       |
| 799.56           | <1x10^-6| 90.11±32.72                  | 7.11±5.92                    |
| 800.56           | <1x10^-6| 64.7±23.62                   | 5.92±4.26                    |
| 769.58 (SM)      | <1x10^-6| 94.32±34.4                   | 9.06±5.37                    |
| 828.57           | <1x10^-6| 14.17±4.68                   | 3.32±2.06                    |
| 849.65           | <1x10^-6| 13.13±4.42                   | 2.93±2.09                    |
| 770.56           | <1x10^-6| 56.06±20.65                  | 7.46±4.99                    |
| 773.54           | <1x10^-6| 30.43±18.96                  | 5.18±3.47                    |
| 755.58 (SM)      | <1x10^-6| 14.11±5.83                   | 6.11±3.92                    |
| 753.60 (SM)      | <1x10^-6| 70.94±31.10                  | 10.69±7.62                   |
| 771.57 (SM)      | <1x10^-6| 27.07±10.97                  | 6.23±2.62                    |
| 783.79 (SM)      | <1x10^-6| 99.88±38.85                  | 42.26±21.45                  |
| 797.60 (SM)      | <1x10^-6| 17.00±6.60                   | 10.27±3.59                   |

Table II. Lipid peaks with higher expression in GBT samples compared TBT samples.

| Bio-marker (m/z) | P-value | Expression in TBT (mean ± SD) | Expression in GBT (mean ± SD) |
|------------------|---------|-------------------------------|-------------------------------|
| 758.60           | <1x10^-6| 11.31±4.45                   | 142.89±64.64                  |
| 759.60 (SM)      | <1x10^-6| 6.84±5.15                    | 62.44±30.06                   |
| 786.64           | <1x10^-6| 11.49±5                      | 88.97±43.94                   |
| 808.60           | <1x10^-6| 11.79±4.41                   | 26.3±13.68                    |
| 616.17           | <1x10^-6| 23.52±26.34                  | 264.5±37.96                   |
| 617.07           | <1x10^-6| 15.61±17.58                  | 189.39±211.06                 |
| 618.17           | <1x10^-6| 6.52±5.76                    | 70.8±82.58                    |
| 614.16           | <1x10^-6| 3.6±2.9                      | 23.38±25.52                   |
| 678.47           | <1x10^-6| 2.91±1.34                    | 22.32±13.36                   |
| 703.43 (SM)      | <1x10^-6| 2.50±1.00                    | 40.01±28.42                   |
| 729.45 (SM)      | <1x10^-6| 3.28±1.60                    | 16.56±8.60                    |
| 731.48 (SM)      | <1x10^-6| 18.51±15.14                  | 85.24±45.36                   |
| 741.54 (SM)      | <1x10^-6| 7.82±4.55                    | 10.49±5.70                    |
| 757.57 (SM)      | <1x10^-6| 12.39±4.88                   | 19.34±7.93                    |
| 781.59 (SM)      | <1x10^-6| 10.40±4.58                   | 20.64±8.47                    |
| 811.62 (SM)      | <1x10^-6| 13.46±6.05                   | 21.62±11.03                   |

GBT, glioma brain tissue; SD, standard deviation; SM, sphingomyelin; TBT, trauma brain tissue.
example, its expression intensity in normal control TBT samples was as high as 198.68, while its expression in GBT was decreased to 14.34.

Among these lipid peaks, the 758.60, 786.64, 617.07, 703.43 and 731.48 m/z peaks exhibited markedly higher expression intensity in GBT samples compared with TBT samples. Taking the peak of 758.60 m/z as an example, its expression value in GBT was as high as 142.89, while its expression in normal control TBT was decreased to 11.31. Some of the differentially expressed lipid peaks in Tables I and II have the potential to serve as clinical diagnosis biomarkers for the detection and treatment of glioma.

**Identification of lipid peaks.** A total of 31 lipid peaks were detected using MALDI-TOF-MS, and 14 of these lipid peaks were identified as sphingomyelin (SM) using the second mass spectrum. These 14 peaks are listed and marked in Tables I and II with the label ‘SM’. The SM peak with the m/z value of 769.58 had an intensity of 94.32 in TBT and the SM peak with the m/z value of 753.60 had an intensity of 70.94 in TBT (Table I). Table III shows the structural data for nine SM peaks.

---

**Verification of the expression of lipid peaks with MALDI-imaging.** A total of 14 peaks were identified as SM. Due to the important role of SM in cell signal transduction, verification of the expression of SM peaks with MALDI-imaging was performed. Fig. 1 shows the MALDI-imaging results of four SM peaks. The sample patterns on the left are the MALDI-imaging results from TBT samples and the sample patterns on the right are the MALDI-imaging results from GBT samples. The expression intensities of the SM peaks with
m/z values of 769.58, 771.57, 797.60, 783.79 and 753.60 were higher in the normal control TBT samples compared with the GBT samples. The expression intensities of the SM peaks with m/z values of 741.54, 781.59, 759.60, 757.57, 731.48 and 703.43 were higher in GBT samples compared with normal control TBT samples. The results of the MALDI-imaging experiments were consistent with the expression intensity results from the MALDI-TOF-MS experiments.

Regulation and control of the expression properties of insulin-like growth factor-1 receptor (IGF-1R) and the PI3K/AKT pathway. Firstly, SM biomarkers, which were differentially expressed between GBT and TBT samples, were identified. Subsequently, the regulation of IGF-1R and the PI3K/AKT pathway by ceramide were investigated. The regulatory effect of ceramide on IGF-1R and the PI3K/Akt pathway was investigated using the glioma cell line U373-MG.

Distribution of ceramide and IGF-1R on the cell membrane. The distribution characteristics of ceramide and IGF-1R on the cell membrane were observed by immunostaining. Fig. 2A shows the distribution of ceramide, as revealed by immunostaining. It was identified that ceramide was made up of lipid rafts, and large quantities of ceramide aggregated to form an areatus-like distribution. Fig. 2B shows the live staining pattern of IGF-1R relative to ceramide. It was revealed that IGF-1R formed an areatus-like distribution that was similar to the distribution of ceramide.

Observation of the movement of IGF-1R with live staining technology. The movement of IGF-1R, a ceramide receptor (19), on the cell membrane was recorded with live staining technology. Fig. 3 illustrates the movement of IGF-1R, as visualized with live cell staining technology. The cell dish was placed into a CO2 incubator and observed via confocal microscopy at 37°C with 5% CO2. The recording times were 0, 5, 10 and 20 min. At 0 min, IGF-1R fluorescence was observed on the cell membrane, whereas IGF-1R fluorescence in the inner area of some cells was not clear. As the recording time increased, the IGF-1R fluorescence in the inner area of cells increased. When the recording time reached 20 min, the inner area of numerous cells presented high fluorescence intensity. IGF-1R fluorescence was indicated with arrows in Fig. 3.

Regulation of the expression of IGF-1R. Data from Fig. 4 indicated that the expression level of phosphorylated IGF-1R was markedly stimulated by insulin when the glioma cell line

Table III. Structural data of various sphingomyelin peaks.

| Biomarker (m/z) | Common name     | Chemical composition                   |
|---------------|-----------------|----------------------------------------|
| 741.54        | SM(d18:1/16:0)  | [C39H79N2O6P+K] 1+                     |
| 755.58        | SM(d18:1/17:0)  | [C40H81N2O6P+K] 1+                     |
| 757.57        | SM(d18:0/17:0)  | [C40H83N2O6P+K] 1+                     |
| 769.58        | SM(d18:1/18:0)  | [C41H83N2O6P+K] 1+                     |
| 771.57        | SM(d18:0/18:0)  | [C41H85N2O6P+K] 1+                     |
| 797.60        | SM(d18:1/20:0)  | [C43H87N2O6P+K] 1+                     |
| 811.62        | SM(d16:1/23:0)  | [C44H89N2O6P+K] 1+                     |
| 783.79        | SM(d18:1/19:0)  | [C42H85N2O6P+K] 1+                     |
| 729.45        | SM(d18:0/15:0)  | [C38H79N2O6P+K] 1+                     |

Figure 5. Expression levels of proteins associated with the PI3K/Akt pathway. Western blotting results of phosphorylated and total Src, S6k and Akt levels. U373-MG cells were treated with insulin for 0, 15, 30 and 60 min. One group of cells was treated with DMSO while the other group was treated with Desi. P-, phosphorylated; S6k, ribosomal protein S6 kinase B1; Src, SRC proto-oncogene non-receptor tyrosine kinase; T-, total; Desi, desipramine.

Figure 6. Western blotting quantitative result for P-Akt. U373-MG cells were treated with insulin for 0, 15, 30 and 60 min. One group of cells was treated with DMSO whereas the other group was treated with Desi. Desi, desipramine.
U373-MG was treated with DMSO as a control. Compared with the fluorescence intensity at 0 min in the DMSO group and the fluorescence intensity at 0 min in the Desi group, the expression level of phosphorylated IGF-1R was significantly decreased when U373-MG cells were treated with Desi. In the DMSO group, the fluorescence intensity of phosphorylated IGF-1R was higher when the cells were stimulated with insulin for 30 min. In the Desi group, the fluorescence intensity of phosphorylated IGF-1R was not markedly increased when cells were further stimulated with insulin for 30 min.

Regulation of the PI3K/Akt pathway. Results on the PI3K/Akt pathway regulation are presented in Fig. 5. The expression intensity of phosphorylated-(P-)Akt, P-SRC proto-oncogene non-receptor tyrosine kinase (Src) and P-ribosomal protein S6 kinase B1 (S6k) in DMSO group increased gradually with increasing time of treatment with insulin. Furthermore, the influence of insulin in Desi group was weakened by the application of Desi. Taking the P-Akt as an example, its quantitative result is shown in Fig. 6. The relative intensity of P-Akt in group DMSO at 0 min is 0.70, while that in group Desi decreases to 0.16. Furthermore, the relative intensity of P-Akt in group Desi are less than that in group DMSO at 15, 30 and 60 min.

Discussion

In the present study, MALDI-imaging and MALDI-TOF-MS were used to investigate the differences in the expression levels of lipid biomarkers in GBT and TBT samples. A total of 31 lipid peaks with differential expression properties were detected in the GBT and TBT samples. A total of 15 lipid peaks exhibited higher expression intensity in TBT compared with GBT samples. Furthermore, 14 lipid peaks were identified as sphingomyelin peaks. As previously reported, sphingomyelin can be hydrolyzed into ceramide via acid sphingomyelinate (ASM) (20,21). The results demonstrated that ceramide and IGF-1R had similar membrane distribution. The live cell staining results indicated that IGF-1R slowly entered the cell from the cell membrane, resulting in increased IGF-1R fluorescence in the inner area of cell. These results were in accordance with a previous study that reported that ceramide can bind to IGF-1R and is involved in cell signal transduction (22). The drug Desi was able to inhibit the accumulation of ceramide on the cell membrane. Insulin was able to stimulate IGF-1R expression, although IGF-1R expression was inhibited by treatment with Desi. Similar results were also observed for the expression levels of proteins P-Src, P-Akt and P-S6k from the PI3K/Akt signaling pathway. Previous studies reported that the dysregulation of the IGF-1R signaling pathway results in the development of malignant gliomas (19,23,24). In addition, glioma cell senescence and apoptosis can be influenced by the activity of the PI3K/Akt signaling pathway (25,26).

Due to the difficulty of obtaining brain tissues, only three GBT samples and three normal control TBT samples were collected and used in the present study. For MALDI-imaging, it is advantageous to obtain cancer tissues and normal tissues from the same individual; however, it is difficult to perform experiments on glioma tissue and normal brain tissue from the same person. Therefore, the brain tissues for glioma research were usually collected from different individuals (27-29). The results of the present study were based on a limited sample size, and the findings would be more valuable and reliable if they were based on a larger sample size. These first-stage results may serve as the research foundation for further studies. There are several topics requiring further investigation, including how the opposite alterations in the same type of lipid biomarkers may be used to form a diagnostic pattern for patients with glioma. Additionally, it should be investigated how to predict the functional effect of these differentially expressed lipid biomarkers between GBT and normal TBT by pathway enrichment analysis. In the future, these issues will be addressed in a study with a larger sample size.

In conclusion, the present study demonstrated that sphingomyelin peaks may be identified as biomarkers in GBT samples compared with normal control TBT samples. Furthermore, insulin could stimulate the high expression of ceramide and of P-Akt from the PI3K/Akt signaling pathway. However, Desi inhibited the increase in ceramide and P-Akt expression. Future study will investigate the association between these sphingomyelins and the survival rate of patients with glioma, and the expression intensity variation of these sphingomyelin along with the clinical treatment process of patients with glioma.

Acknowledgements

The authors would like to thank Dr Zuogang Guo (China Southern Power Grid Company Limited) for critically evaluating this manuscript and technical assistance.

Funding

This work was supported by the National Natural Science Foundation of China (grant no. 30901731) and the Natural Science Foundation of Guangdong Province (grant no. 2016A030310187).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

XZ collected the samples and performed the study. JX participated in the data analysis and manuscript preparation. JY provided support in experimental design and manuscript preparation. HS and SZ contributed to the conception and design of this research plan. HS and SZ also participated in the research data discussion, and critically revised this manuscript. All authors read and approved the manuscript.

Ethics approval and consent to participate

The study protocol was approved by the Ethics Committee of The First Affiliated Hospital of Zhejiang University and The Second Affiliated Hospital of Zhejiang University. Written
informed consent was obtained from participants for the use of their tissues in the present study.

Patient consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

References

1. Schwartzbaum JA, Fisher JL, Aldape KD and Wrench M: Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2: 494-503, 2006.

2. Ohashi R, Matsuda Y, Ishiwata T and Naito Z: Downregulation of fibroblast growth factor receptor 2 and its isoforms correlates with a high proliferation rate and poor prognosis in high-grade glioma. Oncol Rep 32: 1163-1169, 2014.

3. Buczko W, Bartels U, Bouffet E, Becher O and Hawkins C: Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: Diagnostic and therapeutic implications. Acta Neuropathol 128: 573-581, 2014.

4. Miller JJ and Wen PY: Emerging targeted therapies for glioma. Expert Opin Emerg Drugs 21: 441-452, 2016.

5. Yun DP, Wang YQ, Meng DL, Zhu M, Liu Z and Liu RJ: MiR-323-5p acts as a tumor suppressor by targeting the insulin-like growth factor 1 receptor in human glioma cells. Asian Pac J Cancer Prev 15: 10181-10185, 2014.

6. Liu J, Liu Y, Cui Y, Wang X and Liu X: Enolase-phosphatase 1 as a novel potential malignant glioma indicator promotes cell proliferation and migration. Oncol Rep 40: 2233-2241, 2018.

7. Su L, Wang Y, Zhang YT, Geng YP, Si LS and Wang YL: Proteomics-based analysis of a pair of glioma cell lines with different tumor forming characteristics. Neurosci Lett 504: 59-64, 2006.

8. Tan J, Liu M, Zhang JY, Yao XL, Wang YX, Lin Y, Song K, Tan J, Wu JR, Cui YH, et al: Capillary morphogenesis protein 2 is a novel prognostic biomarker and plays oncogenic roles in glioma. J Pathol 245: 160-171, 2018.

9. Hayashi T, Hayakawa Y, Koh M, Tomita T, Nagai S, Kashiwazaki D, Sugimori M, Origa H and Kuroda S: Impact of a novel biomarker, T-LAK cell-originating protein kinase (TOPK) expression on outcome in malignant glioma. Neuropathology 38: 144-153, 2018.

10. Ribom D, Westman-Brinkmalm A, Smits A and Davidson P: Elevated levels of alpha-2-Heremans-Schmid glycoprotein in CSF of patients with low-grade gliomas. Tumour Biol 24: 94-99, 2003.

11. Iwadate Y, Sakaida T, Higasa T, Nagai Y, Ishikuru H, Takiguchi M and Yamaura A: Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 64: 2496-2501, 2004.